Pharmacovigilance Statement Released by ACR

A position statement has been released by the American College of Rheumatology (ACR), emphasizing the need for pharmacovigilance and better monitoring of new pharmaceutical drugs once they have entered the market. 

“Most new medications are approved for marketing after only a limited period of testing on a relatively small group of patients,” said Donald R. Miller, PharmD, FASHP, member of the ACR’s Committee on Rheumatologic Care and co-author of the position statement. “This statement puts us on record of supporting prompt reporting of new and unexpected side effects to the FDA and advocating for more comprehensive systems to observe drug safety in practice.” 

With new drugs like biosimilars, ACR is aware that prompt reporting needs to be done on these medications so both clinicians and patients are aware of the drug safety and that both are reporting adverse events. 

SOURCE: Newswise